High-dose adjuvant interferon therapy for melanoma.
High-dose interferon has recently been approved as an adjuvant to surgery for treating newly diagnosed patients at high-risk for melanoma, particularly those with regional lymph node disease. The data supporting the indications for treatment and its side effects are reviewed.
Licata
A G
AG
Department of Medicine, University of Vermont College of Medicine, Burlington, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D018579:Patient Selection; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins